PE20221783A1 - Anticuerpos anti-axl y composiciones - Google Patents
Anticuerpos anti-axl y composicionesInfo
- Publication number
- PE20221783A1 PE20221783A1 PE2022001857A PE2022001857A PE20221783A1 PE 20221783 A1 PE20221783 A1 PE 20221783A1 PE 2022001857 A PE2022001857 A PE 2022001857A PE 2022001857 A PE2022001857 A PE 2022001857A PE 20221783 A1 PE20221783 A1 PE 20221783A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody
- sequences seq
- amino acid
- seq
- acid sequences
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982852P | 2020-02-28 | 2020-02-28 | |
| PCT/IB2021/051636 WO2021171257A1 (en) | 2020-02-28 | 2021-02-26 | Anti-axl antibodies and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221783A1 true PE20221783A1 (es) | 2022-11-16 |
Family
ID=75426640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001857A PE20221783A1 (es) | 2020-02-28 | 2021-02-26 | Anticuerpos anti-axl y composiciones |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11807688B2 (https=) |
| EP (1) | EP4110824A1 (https=) |
| JP (1) | JP7748377B2 (https=) |
| KR (1) | KR20220148237A (https=) |
| CN (1) | CN115210263A (https=) |
| AR (1) | AR121441A1 (https=) |
| AU (1) | AU2021225490B2 (https=) |
| BR (1) | BR112022015977A2 (https=) |
| CA (1) | CA3170975A1 (https=) |
| CL (1) | CL2022002259A1 (https=) |
| CO (1) | CO2022012159A2 (https=) |
| IL (1) | IL295596A (https=) |
| MX (1) | MX2022010670A (https=) |
| MY (1) | MY209381A (https=) |
| PE (1) | PE20221783A1 (https=) |
| PH (1) | PH12022552041A1 (https=) |
| WO (1) | WO2021171257A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026001894A1 (zh) * | 2024-06-24 | 2026-01-02 | 上海医药集团生物治疗技术有限公司 | 靶向axl的嵌合抗原受体及其用途 |
| CN121851176A (zh) * | 2024-11-28 | 2026-04-14 | 北京大学深圳研究生院 | 抗人axl抗体、基因及其应用 |
| CN119912586B (zh) * | 2024-12-31 | 2025-09-30 | 四川省肿瘤医院 | 基于受体酪氨酸激酶家族axl改造的嵌合抗原受体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| AU2008321835B2 (en) | 2007-11-15 | 2014-11-20 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody capable of binding to anexelekto, and use thereof |
| CA2759836A1 (en) * | 2009-05-11 | 2010-11-18 | U3 Pharma Gmbh | Humanized axl antibodies |
| RU2577986C2 (ru) | 2010-06-18 | 2016-03-20 | Дженентек, Инк. | Антитела против axl и способы их применения |
| MA38165A1 (fr) * | 2012-11-08 | 2018-07-31 | Hoffmann La Roche | Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3 |
| GB201410826D0 (en) * | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| AU2015366213B2 (en) | 2014-12-18 | 2021-10-07 | Bergenbio Asa | Anti-Axl antagonistic antibodies |
| PL3319993T3 (pl) * | 2015-07-10 | 2020-07-27 | Genmab A/S | Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka |
| ES2924402T3 (es) * | 2015-10-02 | 2022-10-06 | Symphogen As | Anticuerpos anti-PD-1 y composiciones |
| PH12018502112B1 (en) * | 2016-04-12 | 2024-03-27 | Servier Lab | Anti-tim-3 antibodies and compositions |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| CA3095986A1 (en) * | 2018-04-10 | 2019-10-17 | Genmab A/S | Axl-specific antibodies for cancer treatment |
-
2021
- 2021-02-26 US US17/186,465 patent/US11807688B2/en active Active
- 2021-02-26 MX MX2022010670A patent/MX2022010670A/es unknown
- 2021-02-26 IL IL295596A patent/IL295596A/en unknown
- 2021-02-26 AU AU2021225490A patent/AU2021225490B2/en active Active
- 2021-02-26 CA CA3170975A patent/CA3170975A1/en active Pending
- 2021-02-26 BR BR112022015977A patent/BR112022015977A2/pt unknown
- 2021-02-26 MY MYPI2022004441A patent/MY209381A/en unknown
- 2021-02-26 WO PCT/IB2021/051636 patent/WO2021171257A1/en not_active Ceased
- 2021-02-26 CN CN202180017213.3A patent/CN115210263A/zh active Pending
- 2021-02-26 JP JP2022551247A patent/JP7748377B2/ja active Active
- 2021-02-26 EP EP21717200.6A patent/EP4110824A1/en active Pending
- 2021-02-26 PH PH1/2022/552041A patent/PH12022552041A1/en unknown
- 2021-02-26 PE PE2022001857A patent/PE20221783A1/es unknown
- 2021-02-26 KR KR1020227033462A patent/KR20220148237A/ko active Pending
- 2021-02-26 AR ARP210100499A patent/AR121441A1/es unknown
-
2022
- 2022-08-18 CL CL2022002259A patent/CL2022002259A1/es unknown
- 2022-08-25 CO CONC2022/0012159A patent/CO2022012159A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11807688B2 (en) | 2023-11-07 |
| KR20220148237A (ko) | 2022-11-04 |
| AU2021225490A1 (en) | 2022-09-15 |
| MX2022010670A (es) | 2022-09-23 |
| PH12022552041A1 (en) | 2023-11-29 |
| BR112022015977A2 (pt) | 2022-10-11 |
| US20210269532A1 (en) | 2021-09-02 |
| AU2021225490B2 (en) | 2025-11-27 |
| CA3170975A1 (en) | 2021-09-02 |
| JP2023515821A (ja) | 2023-04-14 |
| AR121441A1 (es) | 2022-06-08 |
| MY209381A (en) | 2025-07-04 |
| CL2022002259A1 (es) | 2023-04-14 |
| JP7748377B2 (ja) | 2025-10-02 |
| IL295596A (en) | 2022-10-01 |
| EP4110824A1 (en) | 2023-01-04 |
| CN115210263A (zh) | 2022-10-18 |
| CO2022012159A2 (es) | 2022-10-31 |
| WO2021171257A1 (en) | 2021-09-02 |
| TW202146455A (zh) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221783A1 (es) | Anticuerpos anti-axl y composiciones | |
| AR124240A2 (es) | Un anticuerpo biespecífico anti-vegf / anti-ang-2, ácido nucleico, vector de expresión, célula huésped y un método de preparación del anticuerpo | |
| PE20240086A1 (es) | Anticuerpos anti-cd122 y usos de estos | |
| PE20190514A1 (es) | Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123 | |
| AR125394A2 (es) | Métodos y composiciones para la expresión génica en plantas | |
| PE20230160A1 (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos | |
| PE20091172A1 (es) | Anticuerpos bivalentes biespecificos | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| AR094141A1 (es) | Composiciones y metodos para proteinas de accion prolongada | |
| AR111207A1 (es) | Anticuerpos anti-lag3 | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| PE20240802A1 (es) | Anticuerpos multiespecificos con especificidad para il-4r e il-31 | |
| EA200870555A1 (ru) | Слитые белки, их применение и способы их получения | |
| EA201891127A1 (ru) | Нуклеиновые кислоты, кодирующие повторяющиеся аминокислотные последовательности с высоким содержанием пролиновых и аланиновых остатков, имеющие нуклеотидные последовательности с низкой повторяемостью | |
| PE20231511A1 (es) | Moleculas biespecificas de celulas t activadas por proteasas que se unen especificamente al receptor 1 de folato (folr1) y cd3 | |
| PE20130205A1 (es) | Proteinas de union a il-1 | |
| AR085955A1 (es) | Proteinas de union al antigeno | |
| CL2008002349A1 (es) | Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células. | |
| PE20231444A1 (es) | Moleculas de anticuerpo contra el virus bk | |
| AR109450A1 (es) | Moléculas de unión a ilt7 y métodos de uso de las mismas | |
| PE20210119A1 (es) | Anticuerpos anti-apoc3 y metodos de uso de estos | |
| PE20021098A1 (es) | ANTICUERPOS ESPECIFICOS DE CD44v6 | |
| AR130991A2 (es) | PROTEÍNAS DE UNIÓN A TGF-b-RII | |
| AR129991A1 (es) | Anticuerpos que se unen a la pad4 humana y usos de los mismos |